Grace Therapeutics, Inc.
GRCE
$2.72
-$0.08-2.86%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 65.52% | 71.18% | 72.70% | 69.71% | -124.83% |
| Total Depreciation and Amortization | -66.67% | -81.48% | 113.89% | -91.13% | -84.48% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -106.66% | -109.35% | -99.59% | -93.17% | 4,884.39% |
| Change in Net Operating Assets | 168.18% | 206.49% | 386.76% | -807.18% | -289.65% |
| Cash from Operations | -3.44% | 23.28% | 42.08% | 22.50% | 13.74% |
| Capital Expenditure | -175.00% | -175.00% | -120.00% | -29.41% | 11.11% |
| Sale of Property, Plant, and Equipment | -99.09% | -99.09% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 522.72% | 100.00% | 100.00% | -99.89% | -119.00% |
| Cash from Investing | 550.96% | -120.79% | 184.76% | -99.21% | -117.77% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -100.00% | 6,651.38% | 2,320.72% | 2,320.72% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.00% | -100.00% | 6,651.38% | 2,320.72% | 2,320.72% |
| Foreign Exchange rate Adjustments | -- | -- | 109.52% | 100.00% | -106.61% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2.68% | -49.16% | 86.63% | -97.65% | -13.64% |